Literature DB >> 24488618

Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.

Jian Wang1, Zhen-Bin Ma, Kun Li, Guang-Hong Guo.   

Abstract

The aim of this study is to investigate the associations between EZH2 gene polymorphisms and colorectal cancer (CRC) risk. We undertook a case-control study to analyze three EZH2 polymorphisms (148505302C>T, 2110+6A>C and 626-394T>C) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 512 patients with CRC and 546 control participants, and performed EZH2 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in 2,110+6A>C. Nevertheless, 148505302C>T genotype demonstrated a protective effect in CRCs (P=0.014; odds ratio (OR) 0.777, CI 95%:0.647-0.933). Furthermore, 148505302 T allele CRC was more significantly common in patients with tumor size of <4 cm than C allele CRC and in cases of good differentiation and lower advanced pathological stage. However, 626-394T>C genotype was at increased risk of CRCs (P<0.001; odds ratio (OR) 1.457, CI 95%:1.160-1.829). Moreover, 626-394C/C genotype CRCs were more significantly common in patients with tumor size of >4 cm than T allele CRC and in cases of poor differentiation and lower advanced pathological stage. In conclusion, polymorphism in 626-394T>C was observed to be associated with susceptibility of CRC. However, 148505302C>T polymorphism indicated to play a protective role in susceptibility to CRC. Nevertheless, further investigation with a larger sample size is needed to support our results.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488618     DOI: 10.1007/s12032-014-0874-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Control of developmental regulators by Polycomb in human embryonic stem cells.

Authors:  Tong Ihn Lee; Richard G Jenner; Laurie A Boyer; Matthew G Guenther; Stuart S Levine; Roshan M Kumar; Brett Chevalier; Sarah E Johnstone; Megan F Cole; Kyo-ichi Isono; Haruhiko Koseki; Takuya Fuchikami; Kuniya Abe; Heather L Murray; Jacob P Zucker; Bingbing Yuan; George W Bell; Elizabeth Herbolsheimer; Nancy M Hannett; Kaiming Sun; Duncan T Odom; Arie P Otte; Thomas L Volkert; David P Bartel; Douglas A Melton; David K Gifford; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

2.  Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.

Authors:  Jay D Raman; Nigel P Mongan; Satish K Tickoo; Stephen A Boorjian; Douglas S Scherr; Lorraine J Gudas
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.

Authors:  Yasuko Matsukawa; Shuho Semba; Hirotaka Kato; Akihiko Ito; Kazuyoshi Yanagihara; Hiroshi Yokozaki
Journal:  Cancer Sci       Date:  2006-06       Impact factor: 6.716

4.  An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.

Authors:  F Crea; L Fornaro; E Paolicchi; G Masi; P Frumento; F Loupakis; L Salvatore; C Cremolini; M Schirripa; F Graziano; M Ronzoni; V Ricci; W L Farrar; A Falcone; R Danesi
Journal:  Ann Oncol       Date:  2011-09-16       Impact factor: 32.976

5.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

Authors:  Ingeborg M Bachmann; Ole J Halvorsen; Karin Collett; Ingunn M Stefansson; Oddbjørn Straume; Svein A Haukaas; Helga B Salvesen; Arie P Otte; Lars A Akslen
Journal:  J Clin Oncol       Date:  2005-12-05       Impact factor: 44.544

6.  Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.

Authors:  Steven M Lipkin; Elizabeth C Chao; Victor Moreno; Laura S Rozek; Hedy Rennert; Mila Pinchev; Diana Dizon; Gad Rennert; Levy Kopelovich; Stephen B Gruber
Journal:  Cancer Prev Res (Phila)       Date:  2010-04-19

Review 7.  The origins of colorectal carcinoma: specific nomenclature for different pathways and precursor lesions.

Authors:  Andrea Tannapfel; Matthias Neid; Daniela Aust; Gustavo Baretton
Journal:  Dtsch Arztebl Int       Date:  2010-10-29       Impact factor: 5.594

8.  Role of KAI1/CD82 polymorphisms in colon cancer risk in Han Chinese population.

Authors:  Zhen-Bin Ma; Kun Li; Jian Wang; Guang-Hong Guo
Journal:  Med Oncol       Date:  2013-07-20       Impact factor: 3.064

9.  High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.

Authors:  Kazunori Kidani; Mitsuhiko Osaki; Takayuki Tamura; Kensaku Yamaga; Kohei Shomori; Kazuo Ryoke; Hisao Ito
Journal:  Oral Oncol       Date:  2008-07-10       Impact factor: 5.337

10.  Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis.

Authors:  Ø Fluge; K Gravdal; E Carlsen; B Vonen; K Kjellevold; S Refsum; R Lilleng; T J Eide; T B Halvorsen; K M Tveit; A P Otte; L A Akslen; O Dahl
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more
  6 in total

1.  Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.

Authors:  Yan-Long Liu; Xu Gao; Yang Jiang; Gan Zhang; Zi-Cheng Sun; Bin-Bin Cui; Yan-Mei Yang
Journal:  J Cancer Res Clin Oncol       Date:  2014-10-19       Impact factor: 4.553

2.  Correlations of EZH2 and SMYD3 gene polymorphisms with breast cancer susceptibility and prognosis.

Authors:  Shao-Jun Ma; Yan-Mei Liu; Yue-Lang Zhang; Ming-Wei Chen; Wei Cao
Journal:  Biosci Rep       Date:  2018-02-02       Impact factor: 3.840

Review 3.  Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.

Authors:  Anthos Christofides; Theodoros Karantanos; Kankana Bardhan; Vassiliki A Boussiotis
Journal:  Oncotarget       Date:  2016-12-20

4.  Effects of four single nucleotide polymorphisms of EZH2 on cancer risk: a systematic review and meta-analysis.

Authors:  Zhixin Ling; Zonghao You; Ling Hu; Lei Zhang; Yiduo Wang; Minhao Zhang; Guangyuan Zhang; Shuqiu Chen; Bin Xu; Ming Chen
Journal:  Onco Targets Ther       Date:  2018-02-16       Impact factor: 4.147

5.  Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population.

Authors:  Zhen-Bin Ma; Guang-Hong Guo; Qiong Niu; Ning Shi
Journal:  Int J Mol Sci       Date:  2014-07-17       Impact factor: 5.923

6.  A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population.

Authors:  Huihui Li; Chunxiao Chang; Yuhong Shang; Ling Qiang; Baoxuan Zhang; Bing Bu; Guohua Ren; Lihua Song; Mao Shang; Jinming Yu
Journal:  Oncotarget       Date:  2017-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.